ROLES OF NF-B IN TRAIL-INDUCED APOPTOSIS
The Rel/NF-B family of transcription factors regulates a number of biological processes, including cell proliferation and differentiation, apoptosis, immune response, and inflammation (14) (15) (16) . Rel/NF-B are normally present in the cytoplasm in association with a family of inhibitors (I Bs) that mask their nuclear localization sequences (17, 18) . Activation of I B kinase (IKK) leads to phosphorylation and degradation of I Bs. As a result, Rel/NF-B are released and translocated to the nucleus, where they bind to DNA and induce the transcription of target genes (15).
Rel/NF-B induce the expression of a number of anti-apoptotic genes, including cellular inhibitors of apoptosis (cIAPs), mitochondrial proteins of the Bcl 2 family such as Bfl-1/A1 and Bcl-X L , A20, manganese superoxide dismutase (MnSOD), IEX-1L, caspase 8/FADD-like IL-1 -converting enzyme (FLICE)-inhibitory protein (c-FLIP), TNF receptor-associated factor 1 (TRAF1) and 2 (TRAF2), and TRAIL receptor 3 (16,19-30) . Numerous studies exist which demonstrate that Rel/NF-B inhibit programmed cell death induced by TNF-, anticancer drugs, and ionizing radiation (16, (31) (32) (33) .
Recently, it has also become clear that Rel/NF-B regulate TRAIL-induced apoptosis. Thus, treatment of TRAIL-resistant pancreatic cancer cell line L3.6 with TRAIL and the NF-B inhibitor NBD (NEMO-binding domain) peptide significantly decreased cell viability and increased apoptosis (34). This effect was most likely due to decreased FLIP levels in L3.6 cells as a result of NF-B inhibition. Prostate cancer cell lines PC3AR and PC3Neo show different TRAIL sensitivities, which are associated with a difference in NF-B levels in these cells (35). Blocking NF-B function by adenoviral transfer of mutated I B increased apoptotic responses, suggesting a direct role for NF-B in this system.
Multiple myeloma (MM) is an incurable disease. TRAIL might represent a new treatment option, since it kills most MM cell lines and MM cells freshly isolated from patients. Treatment with the NF-B inhibitor SN50 enhanced TRAIL-induced apoptosis in sensitive cells and reversed resistance of . Interestingly, treatment with SN50 did not sensitize normal B-lymphocytes towards TRAILinduced apoptosis. Insulin-like growth factor-1 (IGF-1) promotes proliferation of MM cells and protects them against TRAIL-induced apoptosis. In a recent study, IGF-1 was shown to activate NF-B and upregulate the expression of survival factors FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP (37). Overexpression of Akt decreased TRAIL sensitivity of MM cells. Interestingly, treatment of cells with an Akt inhibitor abrogated NF-B activation and prevented the protective effect. These data show that besides NF-B, the PI-3K/Akt pathway is also involved in the regulation of TRAIL sensitivity. An important role for NF-B in TRAIL-induced apoptosis has also been demonstrated in lymphoid cell lines. Thus, acute T-cell leukemia cells (CEM, Jurkat) and BJAB cells (Burkitt lymphoma) treated with NF-B inhibitors showed a significantly increased sensitivity towards TRAIL (38, 39) .
It has been previously reported that TRAIL, but not other TNF family members, induces apoptosis in the majority of melanoma cell lines (40) (41) (42) (43) (44) . The mechanisms of TRAIL resistance of some melanoma cells are not well understood. Lack of response to TRAIL was partially due to a loss of TRAIL receptor expression (41). However, a clear correlation between expression of TRAIL decoy receptors and TRAIL resistance could
